Why Is AstraZeneca Up Today?
AstraZeneca PLC (LSE:AZN) shares rose 0.29% to 14,022p on 16 Nov 2026, leaving the global biopharmaceutical group marginally higher on the London market. A move of this kind is best viewed in context, because daily price changes can be influenced by market-wide sentiment, currency and Commodity swings, and routine portfolio adjustments by institutional investors.
The company's latest update, its nine-month and third-quarter 2026 results published on 30 October 2026, reported total Revenue of USD 46.9 billion for the first nine months, up 7% at constant exchange rates, with core Earnings Per Share up 14% to USD 8.00.
It also reconfirmed its full-year 2026 guidance and reported 12 positive Phase III readouts in the year to date.
Key Highlights
9M total revenue was USD 46,881 million, up 7% at constant exchange rates, while Q3 total revenue was USD 16,209 million, also up 7%.
9M core EPS was USD 8.00, up 14%, and Q3 core EPS was USD 2.79, up 19% at constant exchange rates.
Core operating profit for the nine months was USD 16.4 billion, up 14%.
Full-year 2026 guidance was reconfirmed: mid-to-high single-digit revenue growth and low double-digit core EPS growth.
About AstraZeneca
AstraZeneca PLC, listed as LSE:AZN, is a global science-led biopharmaceutical company that discovers, develops and sells prescription medicines, mainly in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease.
The company has about 180 projects in its pipeline and has delivered 14 new molecular entities against a target of 20 by 2030.
9M and Q3 2026 Results
Product revenue for the nine months was USD 46,768 million, up 8% at actual rates and 6% at constant exchange rates, with alliance revenue up 32%. Reported EPS was USD 5.62, up 11% at constant exchange rates.
The company noted that double-digit growth in Oncology, Respiratory and Immunology, and Rare Disease more than offset headwinds from loss of exclusivity for Farxiga and Brilinta and volume-based procurement in China.
Therapy Area Performance
Oncology was the largest therapy area, with revenue of USD 21.9 billion, up 16% and equal to 47% of the total. BioPharmaceuticals contributed USD 16.7 billion, or 36% of revenue, with Respiratory and Immunology growing 10%.
Chief Executive Pascal Soriot said the company saw continued commercial momentum, driven by its diverse therapy areas and global presence.
Pipeline Progress
AstraZeneca reported 47 approvals in major regions since its previous results announcement, including first approvals for four new medicines, and first Phase III data for three new molecular entities. Positive readouts included Enhertu in first-line HER2-mutant lung cancer and Imfinzi in combination with tarlatamab in small cell lung cancer.
Not every trial met its endpoint, and the company reported these outcomes alongside the positive readouts, as is usual in its quarterly updates.
Guidance
Guidance for 2026 was reconfirmed at constant exchange rates, based on average 2025 rates. Total revenue is expected to grow by a mid-to-high single-digit percentage, core EPS by a low double-digit percentage, and the core tax rate is expected to be between 18% and 22%.
What Investors Should Watch Next
Readers following LSE:AZN may focus on upcoming Phase III readouts and regulatory decisions, growth in oncology and rare disease, the effect of loss of exclusivity on older medicines, and the full-year 2026 results, which will provide the next complete update.
Conclusion
AstraZeneca shares rose 0.29% to 14,022p on 16 Nov 2026, following nine-month results showing revenue up 7%, core EPS up 14% and a pipeline update that included 12 positive Phase III readouts.
Oncology growth, pipeline delivery and full-year guidance are the main themes for investors.






Please wait processing your request...